These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34728569)

  • 1. Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.
    Klanova M; Kazantsev D; Pokorna E; Zikmund T; Karolova J; Behounek M; Renesova N; Sovilj D; Kelemen CD; Helman K; Jaksa R; Havranek O; Andera L; Trneny M; Klener P
    Mol Cancer Ther; 2022 Jan; 21(1):89-99. PubMed ID: 34728569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
    Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
    Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.
    Dunham D; Viswanathan P; Gill J; Manzano M
    J Virol; 2022 Dec; 96(23):e0136022. PubMed ID: 36416587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
    Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.
    Liu Y; Mondello P; Erazo T; Tannan NB; Asgari Z; de Stanchina E; Nanjangud G; Seshan VE; Wang S; Wendel HG; Younes A
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12034-12039. PubMed ID: 30404918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.
    Adams CM; Mitra R; Gong JZ; Eischen CM
    Clin Cancer Res; 2017 Nov; 23(22):7119-7129. PubMed ID: 28855351
    [No Abstract]   [Full Text] [Related]  

  • 9. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
    Wong KY; Chim CS
    J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.
    Tseng HY; Dreyer J; Emran AA; Gunatilake D; Pirozyan M; Cullinane C; Dutton-Regester K; Rizos H; Hayward NK; McArthur G; Hersey P; Tiffen J; Gallagher S
    Int J Cancer; 2020 Oct; 147(8):2176-2189. PubMed ID: 32249419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
    Johnson NA; Savage KJ; Ludkovski O; Ben-Neriah S; Woods R; Steidl C; Dyer MJ; Siebert R; Kuruvilla J; Klasa R; Connors JM; Gascoyne RD; Horsman DE
    Blood; 2009 Sep; 114(11):2273-9. PubMed ID: 19597184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
    Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
    Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Mandhair H; Bacher U; Pabst T
    Curr Issues Mol Biol; 2024 Mar; 46(4):2946-2960. PubMed ID: 38666914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.
    Quentmeier H; Drexler HG; Hauer V; MacLeod RA; Pommerenke C; Uphoff CC; Zaborski M; Berglund M; Enblad G; Amini RM
    PLoS One; 2016; 11(12):e0167599. PubMed ID: 27907212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.
    Rys RN; Wever CM; Geoffrion D; Goncalves C; Ghassemian A; Brailovski E; Ryan J; Stoica L; Hébert J; Petrogiannis-Haliotis T; Dmitrienko S; Frenkiel S; Staiger A; Ott G; Steidl C; Scott DW; Sesques P; Del Rincon S; Mann KK; Letai A; Johnson NA
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Kohler S; Bacher U; Pabst T
    Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.